Telehealth Options for Dermatology Consultations

Why Getting a Dermatologist Has Been Harder Than It Should Be

The math simply doesn't work. That's the honest answer to why your dermatologist appointment is three months out, and it has nothing to do with how the practice is run.

Skin diseases are the fourth leading cause of nonfatal disease burden worldwide, affecting roughly 2.5 billion people. And yet the specialist workforce is staggeringly thin and unevenly distributed. The United States has approximately 34 dermatologists per million people, which already feels sparse. Sub-Saharan Africa had fewer than one per million as recently as 2022. Even within high-income countries, that national average obscures the real picture: rural counties and underserved urban neighborhoods face multi-month waits regardless of what aggregate supply statistics say.

The problem compounds. Chronic skin conditions, including psoriasis, eczema, and dermatitis, have risen roughly 15% over the past decade. More patients, the the same shortage, and a workforce increasingly buckling under burnout. Over half of dermatologists reported it in a 2014 Mayo Clinic survey; a 2024 Physicians Foundation survey found six in ten physicians overall experiencing it frequently. Burned-out doctors see fewer patients, retire earlier, or leave the specialty entirely.

What happens next in that cycle is predictable: if you can navigate the system, you get care; if you can't, you sit with something you're worried about until it becomes something harder to treat.

Telehealth is a real structural response to that gap. But "teledermatology" isn't a single thing. It's a category containing several meaningfully different options, and which one you choose has real clinical consequences. That's what's worth understanding before you book anything.

What Teledermatology Actually Covers — and What It Doesn't

The British Skin Foundation puts the total number of dermatological conditions at roughly 2,000. Teledermatology, across its various formats, can effectively manage around 90% of them, including skin cancer evaluation. That number surprises most people.

Well-suited concerns include new rashes, spots or pigmented lesions, ongoing management of acne, eczema, psoriasis, and rosacea, prescription renewals, and hair and nail issues. Across multiple studies, teledermatology has reduced time to diagnosis by over 75% in some cases. Patient satisfaction exceeds 80%. Cost savings typically run 30 to 50% compared to in-person visits, before you factor in the two hours of driving.

What it handles less well is also real, and the better platforms are straightforward about it. Conditions that require touch, physically feeling a lump, assessing subtle texture changes beneath the surface, don't translate to a screen. Suspicious lesions that need dermoscopy (a magnification technique used to examine skin lesions in detail) with specialized equipment, biopsies, surgical procedures: those require a physical appointment. The clinical literature is clear on this, and so is anyone who has actually worked with these platforms.

One thing worth holding in mind: not all virtual diagnoses carry equal accuracy. The quality of the outcome depends heavily on which modality you use, the quality of the images submitted, and the clinical model the platform employs. That variability is exactly why the distinctions between options matter.

Store-and-Forward: The Asynchronous Option

Store-and-forward is the modality most people don't know by name but have probably encountered in an ad. You submit photographs of your skin concern along with your medical history and a description of symptoms through a platform. A board-certified dermatologist reviews everything on their own schedule and responds with an assessment and treatment plan. No appointment window, no waiting room. Turnaround is typically 24 to 48 hours.

This model held the largest U.S. market segment in teledermatology at 46.61% of revenue share in 2024, according to Grand View Research. Its dominance makes sense once you consider its structural advantages. It requires no sustained internet connection, just enough bandwidth to upload images. It accommodates patients across time zones or with schedules that don't allow for a blocked hour on a Tuesday afternoon. Research published in JMIR Dermatology identified something I find striking here: if you have a concern in a sensitive area, including conditions associated with sexually transmitted infections, you're meaningfully more likely to seek care when you can submit images without showing yourself in real time to another person. The privacy architecture isn't incidental; it changes who actually gets help.

The main limitation is one you can partially control. Diagnostic accuracy in store-and-forward is only as good as the images the patient submits. A 2017 study of 214 patients found that store-and-forward image quality was comparable to uncompressed video and significantly better than lower-resolution compressed video. Poor photos limit what any dermatologist can determine, however skilled. Good lighting, multiple angles, and a ruler or coin in frame for scale are clinically meaningful inputs.

The other limitation is the absence of real-time dialogue. If the dermatologist needs clarification, there's a delay. For straightforward presentations, that's rarely a problem. For complex or actively evolving cases, it matters.

Live Video Visits: The Synchronous Option

Live video visits follow a rhythm closer to a traditional appointment: a scheduled call, a dermatologist on screen, real-time conversation. The format has gained traction for complex cases where the back-and-forth carries real diagnostic weight.

A patient describing a symptom dynamically, demonstrating how a rash changes under pressure, or explaining the timeline of a flare in the nonlinear way human memory actually works, gives a clinician information that a series of still images can't. If a condition shifts with light or movement, video captures something a photograph cannot.

The limitations are logistical and regulatory. Video visits require stable internet, which remains a real barrier in rural areas. They require a scheduled window, eliminating the spontaneous access that store-and-forward provides. And many platforms are constrained by state-based licensing: the dermatologist on screen must hold a license in the state where you're located at the time of the visit.

Insurance adds another layer. Aetna's policy, for example, requires video-based visits and largely excludes audio-only or asynchronous telehealth coverage. Which modality a platform uses is not an administrative detail; it affects whether your plan covers the visit at all.

One technical note that gets overlooked: uncompressed video can match store-and-forward in diagnostic quality, but compressed, lower-resolution video is significantly worse, per the same 2017 study. Your device, your connection speed, and the platform's compression standards all affect what the dermatologist can actually see.

Hybrid Models: When the Visit Starts Online and Ends In Person

The hybrid model addresses a real friction point. The initial consultation happens remotely, either via store-and-forward or live video, and the dermatologist determines from there whether an in-person visit is warranted, what kind, and with what urgency.

Platforms like OnlineDoctor have built this model explicitly. Health systems like Nebraska Medicine have built structured protocols to guide the decision of when virtual care is appropriate versus when to escalate. The logic is sound: patients with straightforward conditions get resolved faster; if you need in-person care, you arrive at a specialist appointment already engaged, with your case framed and your condition already reviewed.

One point worth holding onto: doctors supported by technology can be highly efficient when they have access to all patient information before spending any time on the case. The remote first step doesn't replace the in-person visit. It makes the in-person visit more productive when it's needed.

If you have a new or changing lesion and are trying to decide whether to drive two hours to a specialist, this model offers a sensible path. It's also a reasonable entry point for anyone uncertain about what level of care their concern requires.

How AI Is Being Layered Into These Options

Artificial intelligence is now embedded in several teledermatology platforms, primarily for triage and image pre-analysis. Platforms like DermEngine and SkinVision use ensemble classification models (AI systems that combine multiple algorithms to improve accuracy), achieving 91 to 94% accuracy in commercial validation studies. A retrospective study found that ChatGPT-4, given clinical images combined with patient metadata from a teledermatology platform, achieved 87.7% top-1 diagnostic accuracy (meaning its first-choice diagnosis was correct in nearly 9 out of 10 cases), a meaningful improvement over single-modality data alone.

Where AI adds real value is in throughput and consistency: faster triage, flagging high-risk cases for urgent dermatologist review, maintaining screening quality across large patient volumes where human attention would inevitably vary.

The limitations are substantive, though. The WHO's 2025 digital health assessment identified fragmentation between visual analysis and clinical reporting workflows, insufficient patient education components built into these tools, and confidence metrics too binary to support nuanced clinical decision-making.

The equity problem is worth paying close attention to, partly because it directly contradicts the stated rationale for these tools. AI validation datasets have been disproportionately composed of lighter skin tones, meaning diagnostic accuracy for Fitzpatrick V and VI skin types (the darkest skin tone categories on a standard clinical scale) is measurably lower. Teledermatology's core argument is that it extends care to underserved populations. An AI layer that performs worse on those populations' skin is working directly against that goal.

Patient sentiment reflects another practical constraint. Research consistently shows that patients are hesitant to trust AI-based diagnoses that lack visible dermatologist involvement. Transparency about how AI is being used, and visible confirmation of physician oversight, affects whether patients act on the recommendations they receive.

The most accurate framing the research supports: AI enhances teledermatology's diagnostic speed and consistency; teledermatology provides the human connection AI lacks. Neither replaces the clinician.

Navigating Platforms: What to Look For When Choosing a Service

Two broad platform architectures exist. The first employs dermatologists directly, which produces a more standardized clinical model. The second connects patients to independent dermatologists operating through their own practices, which introduces variability in experience, turnaround, and protocol.

Platforms with strong user feedback for quick access to board-certified dermatologists, prescription support, and usable apps include SkyMD and DermatologistOnCall. Larger players in the broader telehealth space with dermatology access include Teladoc Health, American Well, MDLIVE, Doctor On Demand, and Miiskin. Fast Pace Health offers virtual dermatology as part of a broader urgent-care model, an example of how dermatology access is beginning to appear in non-specialist platforms.

Before signing up for any of them, four questions cut through most of the noise: Is the dermatologist board-certified? Which modality does the platform use? What states do their clinicians hold licenses in? And what is the realistic turnaround time? If a prescription is a likely outcome, confirm the platform has that capability and can route to your pharmacy.

If you're underinsured, subsidized access exists and is worth investigating. Johnson and Johnson's $500,000 sponsorship of George Washington University's EACH TEACH ONE teledermatology initiative, announced in March 2024, is one example of a no-cost or reduced-cost pathway for patients for whom direct-pay creates a real barrier.

Insurance, Medicare, and What to Expect When You Pay

The reimbursement landscape for teledermatology is active and shifting. Any article about it, including this one, has a shelf life.

Medicare is reimbursing eligible clinicians for covered telehealth services through December 31, 2027. Patients may receive services from anywhere in the United States and its territories, including at home. Medicare Part B typically covers skin cancer diagnosis and treatment, chronic conditions including psoriasis, eczema, and rosacea, bacterial, viral, and fungal infections requiring medical treatment, and evaluation of suspicious lesions. Routine and cosmetic procedures are excluded.

A significant rollback took effect October 1, 2025: several pandemic-era telehealth flexibilities expired. Geographic restrictions and approved originating site rules are back in effect for Medicare. Audio-only teledermatology for non-behavioral care is largely no longer covered. If you were relying on pandemic-era flexibility, check current coverage before assuming it still applies.

Private payer variation is wide. Aetna requires video-based visits. Blue Cross Blue Shield policies differ by state plan; some allow home-based telehealth, while others have reverted to originating site restrictions. The practical step is to call your insurer or use the platform's insurance compatibility tool before booking, specifically confirming whether your plan covers the modality the platform uses. Modality is the variable most people don't think to ask about.

If you're uninsured or underinsured, out-of-pocket telehealth costs typically run 30 to 50% below in-person visit costs even without coverage. Comparing a direct-pay telehealth fee to your in-person copay is worth doing before defaulting to either.

Matching Your Skin Concern to the Right Option

This is where understanding the distinctions actually pays off.

For a new rash, spot, or skin change that isn't urgent, store-and-forward is generally the fastest and most accessible first step. Submit clear photos, get a professional read within 24 to 48 hours, escalate if the response warrants it. For ongoing management of a known chronic condition, either modality works, though live video is preferable if the condition is actively changing or if a prescription adjustment requires real-time discussion.

For a suspicious mole or lesion, telehealth triage gets you a professional read quickly; be prepared that dermoscopy or a biopsy is the recommended next step. Telehealth here is the efficient front door, not the final destination. For conditions in sensitive or hard-to-photograph areas, store-and-forward's privacy architecture meaningfully lowers the barrier to seeking care. That's documented, not assumed.

For follow-up after a biopsy result or a prescription check-in, both modalities work well. For patients in rural areas or with limited bandwidth, store-and-forward requires only enough connectivity to upload images, not a sustained video call, which makes it significantly more practical in constrained environments.

Teledermatology isn't a lesser version of in-person dermatology for the conditions it handles well. It's a different path that often moves faster, costs less, and removes barriers that are structural. What makes it work is matching the concern deliberately to the right modality, rather than letting the platform make that choice invisibly, without you understanding what you've opted into.

If you're uncertain where your concern falls, a hybrid platform that triages to in-person care when needed is a sensible place to start. The first consult exists precisely to make that determination.